Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide

Peng Liubao, Wan Xiaomin, Tan Chongqing, Jon Karnon, Chen Gannong, Li Jianhe, Cui Wei, Luo Xia, Cao Junhua

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide'. Together they form a unique fingerprint.

Medicine & Life Sciences